Leucocyte and eosinophil counts predict progression-free survival in relapsed or refractory classical Hodgkin Lymphoma patients treated with PD1 inhibition.


Journal article


Ida Hude, Stephanie Sasse, Paul J. Bröckelmann, Bastian von Tresckow, Jesko Momotow, Andreas Engert, Sven Borchmann
British Journal of Haematology, vol. 181(6), 2018 May 1, pp. 837-840

Cite

APA
Hude, I., Sasse, S., Bröckelmann, P. J., von Tresckow, B., Momotow, J., Engert, A., & Borchmann, S. (2018). Leucocyte and eosinophil counts predict progression-free survival in relapsed or refractory classical Hodgkin Lymphoma patients treated with PD1 inhibition. British Journal of Haematology, 181(6), 837–840.

Chicago/Turabian
Hude, Ida, Stephanie Sasse, Paul J. Bröckelmann, Bastian von Tresckow, Jesko Momotow, Andreas Engert, and Sven Borchmann. “Leucocyte and Eosinophil Counts Predict Progression-Free Survival in Relapsed or Refractory Classical Hodgkin Lymphoma Patients Treated with PD1 Inhibition.” British Journal of Haematology 181, no. 6 (May 1, 2018): 837–840.

MLA
Hude, Ida, et al. “Leucocyte and Eosinophil Counts Predict Progression-Free Survival in Relapsed or Refractory Classical Hodgkin Lymphoma Patients Treated with PD1 Inhibition.” British Journal of Haematology, vol. 181, no. 6, May 2018, pp. 837–40.